18F-PI-2620 is a next-generation tau PET tracer that has demonstrated ability to image the spatial distribution of suspected tau pathology. The objective of this study was to assess the tracer biodistribution, dosimetry, and quantitative methods of 18F-PI-2620 in the human brain. Full kinetic modeling to quantify tau load was investigated. Noninvasive kinetic modeling and semiquantitative methods were evaluated against the full tracer kinetics. Finally, the reproducibility of PET measurements from test and retest scans was assessed. Methods: Three healthy controls (HCs) and 4 Alzheimer disease (AD) subjects underwent 2 dynamic PET scans, including arterial sampling. Distribution volume ratio (DVR) was estimated using full tracer kinetics (reversible 2-tissue-compartment [2TC] model and Logan graphical analysis [LGA]) and noninvasive kinetic models (noninvasive LGA [NI-LGA] and the multilinear reference tissue model [MRTM2]). SUV ratio (SUVR) was determined at different imaging windows after injection. The correlation between DVR and SUVR, effect size (Cohen's d), and test-retest variability (TRV) were evaluated. Additionally, 6 HCs received 1 tracer administration and underwent whole-body PET for dosimetry calculation. Organ doses and the whole-body effective dose were calculated using OLINDA 2.0. Results: A strong correlation was found across different kinetic models (R 2 > 0.97) and between DVR(2TC) and SUVR between 30 and 90 min, with an R 2 of more than 0.95. Secular equilibrium was reached at around 40 min after injection in most regions and subjects. TRV and effect size for SUVR across different regions were similar at 30-60 min (TRV, 3.8%; Cohen's d, 3.80), 45-75 min (TRV, 4.3%; Cohen's d, 3.77) and 60-90 min (TRV, 4.9%; Cohen's d, 3.73) and increased at later time points. Elimination was via the hepatobiliary and urinary systems. The whole-body effective dose was 33.3 ± 2.1 μSv/MBq for an adult female and 33.1 ± 1.4 μSv/MBq for an adult male, with a 1.5-h urinary bladder voiding interval. Conclusion: 18F-PI-2620 exhibits fast kinetics, suitable dosimetry, and low TRV. DVR measured using the 2TC model with arterial sampling correlated strongly with DVR measured by NI-LGA, MRTM2, and SUVR. SUVR can be used for 18F-PI-2620 PET quantification of tau deposits, avoiding arterial blood sampling. Static 18F-PI-2620 PET scans between 45 and 75 min after injection provide excellent quantification accuracy, a large effect size, and low TRV.
18F-PI-2620 is a next-generation tau PET tracer that has demonstrated ability to image the spatial distribution of suspected tau pathology. The objective of this study was to assess the tracer biodistribution, dosimetry, and quantitative methods of 18F-PI-2620 in the human brain. Full kinetic modeling to quantify tau load was investigated. Noninvasive kinetic modeling and semiquantitative methods were evaluated against the full tracer kinetics. Finally, the reproducibility of PET measurements from test and retest scans was assessed. Methods: Three healthy controls (HCs) and 4 Alzheimer disease (AD) subjects underwent 2 dynamic PET scans, including arterial sampling. Distribution volume ratio (DVR) was estimated using full tracer kinetics (reversible 2-tissue-compartment [2TC] model and Logan graphical analysis [LGA]) and noninvasive kinetic models (noninvasive LGA [NI-LGA] and the multilinear reference tissue model [MRTM2]). SUV ratio (SUVR) was determined at different imaging windows after injection. The correlation between DVR and SUVR, effect size (Cohen's d), and test-retest variability (TRV) were evaluated. Additionally, 6 HCs received 1 tracer administration and underwent whole-body PET for dosimetry calculation. Organ doses and the whole-body effective dose were calculated using OLINDA 2.0. Results: A strong correlation was found across different kinetic models (R 2 > 0.97) and between DVR(2TC) and SUVR between 30 and 90 min, with an R 2 of more than 0.95. Secular equilibrium was reached at around 40 min after injection in most regions and subjects. TRV and effect size for SUVR across different regions were similar at 30-60 min (TRV, 3.8%; Cohen's d, 3.80), 45-75 min (TRV, 4.3%; Cohen's d, 3.77) and 60-90 min (TRV, 4.9%; Cohen's d, 3.73) and increased at later time points. Elimination was via the hepatobiliary and urinary systems. The whole-body effective dose was 33.3 ± 2.1 μSv/MBq for an adult female and 33.1 ± 1.4 μSv/MBq for an adult male, with a 1.5-h urinary bladder voiding interval. Conclusion: 18F-PI-2620 exhibits fast kinetics, suitable dosimetry, and low TRV. DVR measured using the 2TC model with arterial sampling correlated strongly with DVR measured by NI-LGA, MRTM2, and SUVR. SUVR can be used for 18F-PI-2620 PET quantification of tau deposits, avoiding arterial blood sampling. Static 18F-PI-2620 PET scans between 45 and 75 min after injection provide excellent quantification accuracy, a large effect size, and low TRV.
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: Olivier Barret; David Alagille; Sandra Sanabria; Robert A Comley; Robby M Weimer; Edilio Borroni; Mark Mintun; Nicholas Seneca; Caroline Papin; Thomas Morley; Ken Marek; John P Seibyl; Gilles D Tamagnan; Danna Jennings Journal: J Nucl Med Date: 2016-12-01 Impact factor: 10.057
Authors: Victor L Villemagne; Vincent Doré; Samantha C Burnham; Colin L Masters; Christopher C Rowe Journal: Nat Rev Neurol Date: 2018-02-16 Impact factor: 42.937
Authors: Nicolas J Guehl; Dustin W Wooten; Daniel L Yokell; Sung-Hyun Moon; Maeva Dhaynaut; Samantha Katz; Kirsten A Moody; Codi Gharagouzloo; Aurélie Kas; Keith A Johnson; Georges El Fakhri; Marc D Normandin Journal: Eur J Nucl Med Mol Imaging Date: 2019-07-22 Impact factor: 9.236
Authors: Sandra Sanabria Bohórquez; Jan Marik; Annie Ogasawara; Jeff N Tinianow; Herman S Gill; Olivier Barret; Gilles Tamagnan; David Alagille; Gai Ayalon; Paul Manser; Thomas Bengtsson; Michael Ward; Simon-Peter Williams; Geoffrey A Kerchner; John P Seibyl; Kenneth Marek; Robby M Weimer Journal: Eur J Nucl Med Mol Imaging Date: 2019-06-28 Impact factor: 9.236
Authors: Michael Schöll; Anne Maass; Niklas Mattsson; Nicholas J Ashton; Kaj Blennow; Henrik Zetterberg; William Jagust Journal: Mol Cell Neurosci Date: 2018-12-07 Impact factor: 4.314
Authors: Andre Mueller; Santiago Bullich; Olivier Barret; Jennifer Madonia; Mathias Berndt; Caroline Papin; Audrey Perrotin; Norman Koglin; Heiko Kroth; Andrea Pfeifer; Gilles Tamagnan; John P Seibyl; Kenneth Marek; Susan De Santi; Ludger M Dinkelborg; Andrew W Stephens Journal: J Nucl Med Date: 2019-11-11 Impact factor: 11.082
Authors: Mengmeng Song; Maximilian Scheifele; Henryk Barthel; Thilo van Eimeren; Leonie Beyer; Ken Marek; Florian Eckenweber; Carla Palleis; Lena Kaiser; Anika Finze; Maike Kern; Alexander Nitschmann; Gloria Biechele; Sabrina Katzdobler; Gèrard Bischof; Jochen Hammes; Frank Jessen; Dorothee Saur; Matthias L Schroeter; Jost-Julian Rumpf; Michael Rullmann; Andreas Schildan; Marianne Patt; Bernd Neumaier; Andrew W Stephens; Boris-Stephan Rauchmann; Robert Perneczky; Johannes Levin; Joseph Classen; Günter U Höglinger; Peter Bartenstein; Guido Boening; Sibylle Ziegler; Victor Villemagne; Alexander Drzezga; John Seibyl; Osama Sabri; Matthias Brendel Journal: Eur J Nucl Med Mol Imaging Date: 2021-05-22 Impact factor: 10.057
Authors: Santiago Bullich; Andre Mueller; Susan De Santi; Norman Koglin; Stephen Krause; June Kaplow; Michio Kanekiyo; Núria Roé-Vellvé; Audrey Perrotin; Aleksandar Jovalekic; David Scott; Michelle Gee; Andrew Stephens; Michael Irizarry Journal: Alzheimers Res Ther Date: 2022-07-27 Impact factor: 8.823
Authors: Andre Mueller; Santiago Bullich; Olivier Barret; Jennifer Madonia; Mathias Berndt; Caroline Papin; Audrey Perrotin; Norman Koglin; Heiko Kroth; Andrea Pfeifer; Gilles Tamagnan; John P Seibyl; Kenneth Marek; Susan De Santi; Ludger M Dinkelborg; Andrew W Stephens Journal: J Nucl Med Date: 2019-11-11 Impact factor: 11.082
Authors: Suzanne L Baker; Karine Provost; Wesley Thomas; A J Whitman; Mustafa Janabi; Mark E Schmidt; Maarten Timmers; Hartmuth C Kolb; Gil D Rabinovici; William J Jagust Journal: J Cereb Blood Flow Metab Date: 2021-07-14 Impact factor: 6.960